Investor Relations

Building the infrastructure for preventive medicine.

We turn a single finger-prick into a continuously learning virtual twin. A dual-engine model monetizing consumer wellness today to build the clinical multi-cancer detection AI of tomorrow.

  • Clinical pilot, Cleveland Clinic Abu Dhabi
  • Microsoft for Startups
  • $5M raised
Our Core Asset

Your blood. 30,000 biomarkers.
Virtual twin.

Standard blood tests read 20 to 30 parameters. BioTwin reads over 30,000 biomarker signals from a single finger-prick using mass spectrometry, creating an unparalleled dataset for predictive AI.

1

One Sample

A simple at-home finger-prick collected over 5 days. No clinic visits, no fasting, friction-free scaling.

2

30,000 Signals

High-resolution mass spectrometry captures a complete metabolic signature, not just a targeted checklist.

3

3 Programs

Raw data is organized into actionable health programs: Healthspan and Longevity, Elite Human Optimization, and Weight Management.

4

Virtual Twin

A living mathematical model that learns retroactively. When our research team adds a new analysis, the twin updates without a new kit.

Go-to-market strategy

Consumer today.
Clinical tomorrow.

The data required to train clinical AI for complex diseases is vast and expensive to acquire. BioTwin solves this cold-start problem through a self-funding data flywheel.

  • TwinMe (Consumer): We deliver immediate value through 3 commercial wellness programmes (Longevity, Elite Optimization, Weight) generating immediate revenue.

  • BioTwin (Clinical): Every anonymized finger-prick continuously expands our multi-omics database, directly training our predictive models for oncology and chronic diseases.

N=1
Personalized
Medicine

"By mapping individual trajectories rather than population averages, we can detect minute biological deviations before they manifest as clinical symptoms."

Scientific Pipeline

Active clinical traction.

Our virtual twin technology is already deployed in real-world clinical environments.

Clinical pilot, active
Abu Dhabi, UAE

Cleveland Clinic Abu Dhabi

BioTwin's first clinical pilot delivers results today through partner physicians at Cleveland Clinic Abu Dhabi. The programme is under the regulatory framework of the United Arab Emirates.

Current screening: Breast cancer · Colorectal cancer

Performance: Current models demonstrate 0.78 sensitivity across 6 cancer types using multi-omics integration.

Research in progress
Global

Broader clinical pipeline

Beyond the UAE pilot, BioTwin runs active research programs globally, supported by over 50 published studies validating our biomarker signatures.

  • Oncology: Lung, Pancreas, Prostate, Ovarian
  • Neurology: Alzheimer's, Parkinson's, Depression
  • Cardiology: Heart failure, Hypertension

These are scientific projects, and TwinMe kit data contributes directly to them.

Industry validation

Global leaders are investing in virtual twin technology as a foundational infrastructure for precision health.

Dassault Systemes

"There will be a before and after the virtual twin of the human body."

The Living Heart Project and Emma Twin initiative are advancing virtual twin technology for cardiac care and personalized medicine.

Nvidia

Healthcare virtual twins powered by AI simulation

NVIDIA's healthcare platforms support accelerated medical simulation and scalable virtual twin infrastructure.

Twin Health

Whole Body Digital Twin for metabolic health

Published peer-reviewed clinical outcomes demonstrating measurable metabolic improvement through twin-based modeling.

Why this matters: Investment by global leaders confirms that virtual twin infrastructure is becoming a foundational layer in precision and preventive healthcare.

Join our mission

We are building the definitive biological dataset for preventive medicine. To access our data room, clinical results, or speak with leadership, reach out today.

Contact Investor Relations